Trials / Completed
CompletedNCT05450198
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-6194 in Participants With Moderate to Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MK-6194 | MK-6194 administered subcutaneously (SC) |
| BIOLOGICAL | Placebo | Placebo comparator to MK-6194 administered SC |
Timeline
- Start date
- 2022-08-08
- Primary completion
- 2024-05-22
- Completion
- 2024-05-22
- First posted
- 2022-07-08
- Last updated
- 2025-06-05
- Results posted
- 2025-06-05
Locations
19 sites across 6 countries: United States, Belgium, Bulgaria, Canada, Romania, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05450198. Inclusion in this directory is not an endorsement.